Adamas Readies NDA After Positive Phase III
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri
The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.
Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
In VC deals, Magenta raised $50m, licensed a Novartis asset and engaged an important partner. Seven public companies revealed financial transactions totaling $947.4m, including Achaogen's $20.5m from the Gates Foundation. Also, OncoMed, Regulus and Depomed provided restructuring updates.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.